| TEL |
Report |
Organic sales growth |
BEAT |
pred ~9.3% vs. cons 8.94% |
MEDIUM |
| TEL |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$2.88 vs. cons $2.85 |
MEDIUM |
| TEL |
Report |
Net sales |
IN-LINE |
pred ~$5.03B vs. cons $5.015B |
MEDIUM |
| TEL |
Guide |
Q4 FY26 net sales |
UNCHANGED |
guide ~$5.20B vs. cons $5.181B |
LOW |
| TEL |
Guide |
Q4 FY26 adjusted EPS |
BETTER |
guide ~$3.00 vs. cons $2.96 |
MEDIUM |
| TEL |
Guide |
FY26 AI revenue outlook |
UNKNOWN |
reaffirmation expected; consensus UNVERIFIED |
LOW |
| TEL |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
LOW |
| TEL |
Return |
5-day cumulative residual |
+4.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — Q4 estimate lift |
LOW |